SWOT Analysis for Natco Pharma Ltd.

Add SWOT widget to your site/app

Benjamin Graham Value Screen
Stocks in Buy Zone with High Momentum Score Last Month
Companies with current TTM PE Ratio less than 3 Year, 5 Year and 10 Year PE
Buy Zone: Stocks in the buy zone based on days traded at current PE and P/BV
Strong Performer, Under Radar Stocks (DVM)
Profit making Companies with High ROCE and Low PE
Companies with 10% increase in share price over three months, with rising net profit growth
Undervalued Growth Stocks
Jim Slater's Zulu Principle (Discover Growth Stocks)
Relative Outperformance versus Industry over 1 Month
Rising Net Cash Flow and Cash from Operating activity
Strong QoQ EPS Growth in recent results
PEG lower than Industry PEG
Stocks gaining versus previous close, open price and RSI
High Momentum Scores (Technical Scores greater than 50)
Relative Outperformance versus Industry over 1 Week
Relative Outperformance versus Industry over 1 Month
Effectively using its capital to generate profit - RoCE improving in last 2 years
Effectively using Shareholders fund - Return on equity (ROE) improving since last 2 year
Efficient in managing Assets to generate Profits - ROA improving since last 2 year
Growth in Net Profit with increasing Profit Margin (QoQ)
Companies with Low Debt
Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years
Annual Net Profits improving for last 2 years
Book Value per share Improving for last 2 years
Companies with Zero Promoter Pledge
Stock with Low PE (PE < = 10)
RSI indicating price strength
Top Gainers
Stocks Outperforming their Industry Price Change in the Quarter

Benjamin Graham Value Screen

Stocks in Buy Zone with High Momentum Score Last Month

Companies with current TTM PE Ratio less than 3 Year, 5 Year and 10 Year PE

Buy Zone: Stocks in the buy zone based on days traded at current PE and P/BV

Strong Performer, Under Radar Stocks (DVM)

Profit making Companies with High ROCE and Low PE

Companies with 10% increase in share price over three months, with rising net profit growth

Undervalued Growth Stocks

Jim Slater's Zulu Principle (Discover Growth Stocks)

Relative Outperformance versus Industry over 1 Month

Rising Net Cash Flow and Cash from Operating activity

Strong QoQ EPS Growth in recent results

PEG lower than Industry PEG

Stocks gaining versus previous close, open price and RSI

High Momentum Scores (Technical Scores greater than 50)

Relative Outperformance versus Industry over 1 Week

Relative Outperformance versus Industry over 1 Month

Effectively using its capital to generate profit - RoCE improving in last 2 years

Effectively using Shareholders fund - Return on equity (ROE) improving since last 2 year

Efficient in managing Assets to generate Profits - ROA improving since last 2 year

Growth in Net Profit with increasing Profit Margin (QoQ)

Companies with Low Debt

Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years

Annual Net Profits improving for last 2 years

Book Value per share Improving for last 2 years

Companies with Zero Promoter Pledge

Stock with Low PE (PE < = 10)

RSI indicating price strength

Top Gainers

Stocks Outperforming their Industry Price Change in the Quarter

Companies with growing costs YoY for long term projects

Companies with growing costs YoY for long term projects

Brokers upgraded recommendation or target price in the past three months
Mutual Funds Increased Shareholding in Past Month
MFs increased their shareholding last quarter
Mutual Funds Increased Shareholding over the Past Two Months
Mf buying for 2 months

Brokers upgraded recommendation or target price in the past three months

Mutual Funds Increased Shareholding in Past Month

MFs increased their shareholding last quarter

Mutual Funds Increased Shareholding over the Past Two Months

Mf buying for 2 months

US FDA Warning Letter

US FDA Warning Letter

Stocks with improving cash flow, with good durability
Rising Delivery Percentage Compared to Prev Day
Average Affordability - Stocks with Medium Trendlyne Valuation Score versus Benchmarks
Average Bullish Trend - Stocks with Medium Trendlyne Momentum Score versus Benchmarks

Stocks with improving cash flow, with good durability

Rising Delivery Percentage Compared to Prev Day

Average Affordability - Stocks with Medium Trendlyne Valuation Score versus Benchmarks

Average Bullish Trend - Stocks with Medium Trendlyne Momentum Score versus Benchmarks

Natco Pharma Ltd. SWOT Analysis: Strengths, Weakness, Opportunity, and Threats

Natco Pharma Ltd. has 30 Strengths, 1 Weaknesses, 5 Opportunities and 1 Threats. The SWOT product gives you a quick x-ray of a stock's outlook and potential